Literature DB >> 17542699

Effects of stimulation of adenosine A2A receptors on lipopolysaccharide-induced production of reactive oxygen species by equine neutrophils.

Wan-chun Sun1, James N Moore, David J Hurley, Michel L Vandenplas, Thomas F Murray.   

Abstract

OBJECTIVE: To assess the anti-inflammatory effects of an adenosine analogue on lipopolysaccharide (LPS)-stimulated equine neutrophils. SAMPLE POPULATION: Neutrophils obtained from 10 healthy horses. PROCEDURES: An adenosine analogue (5'-N-ethylcarboxamidoadenosine [NECA]) was tested for its ability to inhibit production of reactive oxygen species (ROS) in LPS-stimulated equine neutrophils. Selective adenosine receptor antagonists were used to identify the receptor subtype responsible for effects. To assess the mechanism of action of NECA, cAMP concentrations were measured, and effects of dibutyryl cAMP (a stable analogue of cAMP) and rolipram (a type 4 phosphodiesterase inhibitor) were investigated.
RESULTS: NECA elicited concentration-dependent inhibition of ROS production that was inhibited by ZM241385, a selective adenosine A(2A) receptor antagonist; this effect of NECA was not affected by the adenosine A(2B) receptor antagonist MRS1706. Also, ZM241385 blocked NECA-induced increases in cAMP concentrations, whereas MRS1706 did not alter this effect of NECA. Rolipram potentiated NECA-induced inhibition of ROS production, and dibutyryl cAMP also inhibited ROS production. CONCLUSIONS AND CLINICAL RELEVANCE: Activation of adenosine A(2A) receptors inhibited ROS production by LPS-stimulated equine neutrophils in a cAMP-dependent manner. These results suggest that stable adenosine A(2A) receptor agonists may be developed as suitable anti-inflammatory drugs in horses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542699     DOI: 10.2460/ajvr.68.6.649

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  7 in total

Review 1.  Nitroxidative Signaling Mechanisms in Pathological Pain.

Authors:  Peter M Grace; Andrew D Gaudet; Vasiliki Staikopoulos; Steven F Maier; Mark R Hutchinson; Daniela Salvemini; Linda R Watkins
Journal:  Trends Neurosci       Date:  2016-11-12       Impact factor: 13.837

Review 2.  Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions.

Authors:  M A Trevethick; S J Mantell; E F Stuart; A Barnard; K N Wright; M Yeadon
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

3.  Secondary Burn Progression Mitigated by an Adenosine 2A Receptor Agonist.

Authors:  Nathan Haywood; Matthew R Byler; Aimee Zhang; Evan P Rotar; Dustin Money; Sarah E Gradecki; Huy Q Ta; Morgan Salmon; Irving L Kron; Victor E Laubach; J Hunter Mehaffey; Mark E Roeser
Journal:  J Burn Care Res       Date:  2022-01-05       Impact factor: 1.845

Review 4.  Purinergic signalling and immune cells.

Authors:  Geoffrey Burnstock; Jean-Marie Boeynaems
Journal:  Purinergic Signal       Date:  2014-10-29       Impact factor: 3.765

5.  Number of Circulating CD 73-Expressing Lymphocytes Correlates With Survival After Cardiac Arrest.

Authors:  Sergey Ryzhov; Teresa May; John Dziodzio; Ivette F Emery; F L Lucas; Angela Leclerc; Barbara McCrum; Christine Lord; Ashley Eldridge; Michel P Robich; Fumito Ichinose; Douglas B Sawyer; Richard Riker; David B Seder
Journal:  J Am Heart Assoc       Date:  2019-06-25       Impact factor: 5.501

6.  Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.

Authors:  Yu Bai; Xin Zhang; Jie Zheng; Ziyi Liu; Zhenfan Yang; Xiaolin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2022-10-14

7.  Pharmacokinetics and ex vivo anti-inflammatory effects of oral misoprostol in horses.

Authors:  E M Martin; J M Schirmer; S L Jones; J L Davis
Journal:  Equine Vet J       Date:  2018-10-23       Impact factor: 2.888

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.